|
| Press Releases |
|
 |
|
| Monday, October 19, 2020 |
|
|
中國生物製藥副主席兼執行董事鄭翔玲女士及執行董事謝炘先生合共增持公司70萬股股份 |
| 中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈 more info >> |
|
| Friday, August 28, 2020 |
|
|
中国生物制药公布2020年中期业绩 |
| 中国领先的创新研发驱动型医药集团—中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2020年6月30日止六个月（「回顾期」）之未经审核财务业绩。 more info >> |
|
|
中國生物製藥公佈2020年中期業績 |
| 中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2020年6月30日止六個月（「回顧期」）之未經審核財務業績。 more info >> |
|
|
Sino Biopharm Announces 2020 Interim Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2020 (the "review period"). more info >> |
|
| Thursday, May 28, 2020 |
|
|
中国生物制药公布2020年第一季度业绩 |
| 中国领先的创新研发驱动型医药集团—中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2020年3月31日止三个月（「回顾期」）之未经审核财务业绩。 more info >> |
|
|
中國生物製藥公佈2020年第一季度業績 |
| 中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2020年3月31日止三個月（「回顧期」）之未經審核財務業績。 more info >> |
|
|
Sino Biopharmaceutical Announces 2020 First Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2020 ("the review period"). more info >> |
|
| Tuesday, May 26, 2020 |
|
|
中国生物制药与康方生物共同开发派安普利新药上市申请获国家药品监督管理局受理 |
| 中国领先的创新研发驱动型医药集团 — 中国生物制药有限公司（股份代号：1177）宣布，与致力研究、开发、生产及商业化全球病人可负担的创新抗体新药的生物制药公司康方生物科技（开曼）有限公司（「康方生物」；股份代号：9926） more info >> |
|
|
中國生物製藥與康方生物共同開發派安普利新藥上市申請獲國家藥品監督管理局受理 |
| 中國領先的創新研發驅動型醫藥集團 — 中國生物製藥有限公司（股份代號：1177）宣佈，與致力研究、開發、生產及商業化全球病人可負擔的創新抗體新藥的生物製藥公司康方生物科技（開曼）有限公司（「康方生物」；股份代號：9926） more info >> |
|
|
New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration |
| Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the anti PD-1 monoclonal antibody drug more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
三菱重工、西豪州パースに脱炭素事業の営業拠点を設立
Apr 7, 2025 14:00: JST
|
|
|
科技創新價值凸顯 優然牧業2024年盈利提升 現金EBITDA同比增38.3%至53.25億元
Apr 7, 2025 13:54 HKT/SGT
|
|
|
陽光保險：業績穩增彰顯發展韌性 香港資管開業再啟新程
Apr 7, 2025 13:08 HKT/SGT
|
|
|
通通AI社交集團公佈2024年度業績
Apr 7, 2025 13:06 HKT/SGT
|
|
|
洲際航天科技業績期聚焦：百星展覽展示AI賦能衛星製造的未來
Apr 7, 2025 13:03 HKT/SGT
|
|
|
海通恒信：深耕金融“五篇大文章” 2024年業務布局持續優化
Apr 7, 2025 13:01 HKT/SGT
|
|
|
又又又派錢了，很賺錢嗎？
Apr 7, 2025 12:58 HKT/SGT
|
|
|
BCQ Achieves Dual Growth in 2024 Revenue and Net Profit Attributable to Shareholders
Apr 7, 2025 12:24 HKT/SGT
|
|
|
Katalon Study Reveals 20% of AI Testers Fear Job Loss
Apr 7, 2025 10:03 HKT/SGT
|
|
|
Forexiro Makes Its Debut at Cyprus Trading Event, Offering Structured Gold Trading on H4
Apr 7, 2025 10:00: JST
|
|
|
Nghiên cứu của Katalon tiết lộ 20% người kiểm tra AI sợ mất việc
Apr 7, 2025 09:34 HKT/SGT
|
|
|
Forexiro Makes Its Debut at Cyprus Trading Event, Offering Structured Gold Trading on H4
Apr 7, 2025 09:00 HKT/SGT
|
|
|
Integration of ION Mobility's assets and IP, set to accelerate TVS Motor's EV footprint in South East Asian markets
Apr 7, 2025 08:30 HKT/SGT
|
|
|
EdgePoint Towers Appoints Ravin Vickneswaran as Chief Operating Officer
Apr 7, 2025 03:06 HKT/SGT
|
|
|
Fosun's Core Businesses Stay Firm Despite One-off Non-cash Loss
Apr 6, 2025 20:30 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
